Rockland, Massachusetts, December 15, 2016 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the appointment of Brian Barry, Esq., as Chief Compliance Officer. In this role, Mr. Barry will be responsible for the ongoing development and implementation of the company's comprehensive compliance program and will also be a member of the organization’s leadership team.
Mr. Barry joined EMD Serono in January 2011, as Compliance Counsel. In this role, he was integral to the implementation and oversight of a comprehensive compliance program at EMD Serono, which has served as a key component in the company’s ability to deliver on its commitment to integrity.
“Brian’s deep understanding of our business and compliance program is critical to achieving the highest level of legal and ethical standards that all of us at EMD Serono hold ourselves accountable for across our business activities,” said Gary Zieziula, President and Managing Director of EMD Serono. “Brian has demonstrated tremendous leadership and expertise by providing guidance to our cross-functional teams on local and cross-border compliance issues, and has aided in fostering a corporate culture valuing integrity and ethical behavior.”
Prior to joining EMD Serono, Mr. Barry spent several years as an attorney in private practice at Choate, Hall & Stewart LLP, as well as other prominent international law firms, focused in the Government Enforcement and Major Commercial Litigation groups, and represented companies and individuals in government investigations.
Mr. Barry succeeds Daniel Moynihan who was recently appointed to Global Compliance Officer for Life Science at MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany.
Mr. Barry received his J.D. from the University of Virginia School of Law and B.A. from the College of the Holy Cross.
About EMD Serono, Inc.
EMD Serono is the biopharma business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has 1,200 employees around the country with commercial, clinical and research operations based in the company’s home state of Massachusetts.
Melissa Manganello 1-781-681-2393